|
Investor Relations
Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology.
Latest News
Sep 2, 2008
SOMAXON PRESENTS PHARMACOLOGICAL DATA ON DOXEPIN AT THE 21ST EUROPEAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY CONGRESS (pdf)
Aug 28, 2008
Somaxon Pharmaceuticals to Present at the Thomas Weisel 2008 Healthcare Conference and NewsMakers in the Biotech Industry Conference (pdf)
Webcasts
|
| Stock Quote |
SOMX(Common Stock)
Last Trade $4.25
Change  0.37
Exchange NASDAQ
Volume 40,600
09/05/08 4:00 PM ET
Minimum 20 Minute Delay.
Refresh Quote.
|
Annual Report 2007
|
